4.7 Review

Adaptive Servo-Ventilation as a Novel Therapeutic Strategy for Chronic Heart Failure

Journal

JOURNAL OF CLINICAL MEDICINE
Volume 11, Issue 3, Pages -

Publisher

MDPI
DOI: 10.3390/jcm11030539

Keywords

heart failure; hemodynamics; congestion

Ask authors/readers for more resources

New therapeutics have significantly reduced clinical risk for patients with chronic heart failure. Adaptive servo-ventilation is a novel treatment option for patients refractory to conventional therapies. Patients who do not respond to oral medical therapy alone may benefit from these new treatment strategies.
The introduction of new therapeutics for patients with chronic heart failure, including sacubitril/valsartan, sodium-glucose cotransporter 2 inhibitors, and ivabradine, in addition to beta-blockers, angiotensin converting enzyme inhibitors, and mineralocorticoid receptor antagonists, lends an opportunity for significant clinical risk reduction compared to what was available just one decade ago. Further clinical options are needed, however, for patients with residual clinical congestion refractory to these therapies. Adaptive servo-ventilation is a novel therapeutic option to address significant clinical volume in cases resistant to medical therapy. The aggregate benefit of these additional therapeutic strategies in addition to foundational medical therapy may be a promising option in the selected candidates who do not achieve acceptable clinical and quality-of-life improvements with oral medical therapy alone. Now is the era to reconsider the implication of an adaptive servo-ventilation-therapy-incorporated medical therapeutic strategy for patients with congestive heart failure.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available